# Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)

> **NCT01644773** · PHASE1 · COMPLETED · sponsor: **St. Jude Children's Research Hospital** · enrollment: 36 (actual)

## Conditions studied

- Diffuse Intrinsic Pontine Glioma
- High-grade Glioma

## Interventions

- **DRUG:** Crizotinib
- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT01644773
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-27
- **Primary completion:** 2018-03-07
- **Final completion:** 2018-09-28
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01644773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01644773, "Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01644773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*